Recent News
Read ArticleDr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/MUKXC0Tw3M
Dr. John Cush @RheumNow ( View Tweet)
📊 NEW FROM EULAR: Real-world effectiveness of switching to a JAKi after first-line TNFi in PsA
See how second-line treatment choices impacted TJC and SJC in patients from the Adelphi database. Poster sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/GNTl0I6Wbh https://t.co/1V0r9ZBN9Y
Dr. John Cush @RheumNow ( View Tweet)
🆕 Intro to ILD (Part I): the essentials
🫁 Definition & basics
🔬 Key pathology patterns
🧑⚕️ Clinical approach
📋 What rheums need to know
⬇️ Download & learn more: https://t.co/7RzpTDOjwa
Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5
Dr. John Cush @RheumNow ( View Tweet)
💥 New week, new quiz.
Take 90 seconds. Prove you're the rheum news MVP.
📈 Track your accuracy
🏁 Race to the top of the leaderboard
🎯 Review what you missed
Take the RheumIQ quiz ➡️ https://t.co/CASRQjoYrB https://t.co/FCjkqud0y4
Links:
Dr. John Cush @RheumNow ( View Tweet)
Hitting the Target: T2T Therapy in SLE
Treat-to-target strategies are not a new concept in rheumatology. It has shown to improve patient outcomes and quality of life in RA and PsA, and is now being increasingly adopted not only in SLE research but also in clinical practice. This article reviews key highlights from Dr. Eric Morand’s plenary session lecture on Treat to Target in SLE: Current Evidence and Future Directions, presented during the recent APLAR 2025 Congress.
Read Article
Lessons Learned in Neuropsychiatric SLE
Dr. Sheila Reyes, The Philippines, reports highlights from a session on neuropsychiatric systemic lupus erythematosus, presented at the APLAR 2025 Congress in Fukuoka, Japan.
https://t.co/Dh1GQnBhvg https://t.co/wX5FgpIq7C
Dr. John Cush @RheumNow ( View Tweet)
PAH diagnosis and management in the context of CTD ILD
Pulmonary arterial hypertension (PAH) is a serious complication of connective tissue disorders (CTD), affecting about 25% of PAH patients. CTD-PAH is the second most common cause after the idiopathic form. PAH involves high https://t.co/UgsdYWv02S
Dr. John Cush @RheumNow ( View Tweet)
QD Clinic Video: RA and Bronchiectasis
Dr. Jeffrey Sparks, Boston, talks about rheumatoid arthritis and bronchiectasis as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025.
https://t.co/Y2u3m4rFfj https://t.co/KgrIxXlQo4
Dr. John Cush @RheumNow ( View Tweet)
STOP-RA results published in A&R. 144 at risk, CCP+ pts were enrolled to received HCQ vs PBO for 12 mos, w/ 24 mos F/U. Progression to RA seen in 30.4% on HCQ vs 32.9% on PBO (NS; P=0.52). Also IA, Jt Sxs, severity & adverse events were similar between groups.
Dr. John Cush @RheumNow ( View Tweet)
TNR: Future Treatment of ILD
This Tuesday Night Rheumatology webinar reviewed ACR and EULAR guidelines on interstitial lung disease, with a focus on ‘where are we now and where are we going?’ in regards to treatment strategies and emerging therapies in ILD care. https://t.co/F1fJhWgR5O
Dr. John Cush @RheumNow ( View Tweet)
AbbVie's US patent protection for Rinvoq (upadacitinib) will run till April 2037. SEC filing shows AbbVie has reached an agreement with generic manufacturers challenging Rinvoq patents. UPA is their 2nd leading product with nearly $3.75 billion worldwide sales in 1st 1/2 of
Dr. John Cush @RheumNow ( View Tweet)
Antifibrotics - A New Class of Therapies in Rheumatology?
Rheumatologists typically manage systemic autoimmune rheumatic diseases (SARD) and associated interstitial lung disease (ILD) with immunosuppressants. However, evidence increasingly supports also the use of antifibrotic https://t.co/IobQagC0ZE
Dr. John Cush @RheumNow ( View Tweet)
9 yr. study of anti-Ro52 & ILD pts -- 1,026 pts 15% Ro52+: interstitial pneumonia w/ autoimmune 48%, CTD-ILD 13%, idiopathic pulm fibrosis 10%, hypersens pneumonitis 6%, idiopathic ILD 24%. Ro52+ were younger w/ more autoimmune dz, +MSA Abs, ILD progression, death, & lung https://t.co/fuFfnaYIRd
Dr. John Cush @RheumNow ( View Tweet)
Flow cytometry on Peripheral blood can help patient stratification in RA
A cluster rich in TEMRA Terminally Differentiated Effector Memory T Cells is associated with response to treatment and therapeutic decision taking into account showed higher remission 39% vs. 24%
Next https://t.co/8ZZ2epf7LK
Aurelie Najm @AurelieRheumo ( View Tweet)
In #scleroderma pts with cardiac involvement, the presence of ventricular ectopy is assocd w/ ⬆️risk of mortality & SCD.
☝️these arrythmias present late so consider it in pts w/established dse who develop new-onset cardiac symptoms
@RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/MTDfxevqwb
sheila @RHEUMarampa ( View Tweet)
2025 Update of EULAR RA management recommandation
Summary slide inspired from Josef Smolen’s presentation
@RheumNow #APLAR25 https://t.co/wRzeX9OIry https://t.co/djrd7O9G9H
Links:
Aurelie Najm @AurelieRheumo ( View Tweet)
Is it #lupus?
Interesting study by @escheriKYA et al. showing comparable diagnostic performance of SLERPI (93%) in 🇵🇭 patients vs. SLICC and EULAR/ACR criteria
A practical alternative tool that can be used by clinicians in a resource-limited setting 🤔
@RheumNow #APLAR25 https://t.co/xByBkjEr3r
Links:
sheila @RHEUMarampa ( View Tweet)
Key takeaways of trabecular bone screening:
📌Complements but doesnt replace BMD/FRAX in fracture risk assessment
📌Dont exclude any lumbar spine unless w/significant change like laminectomy
📌Can use in monitoring untreated pts since TBS declines
@RheumNow #APLAR25 https://t.co/bcN83IDDja
sheila @RHEUMarampa ( View Tweet)
Remember! ☝️
Trabecular bone screening should not be routinely used in pre-menopausal women.
@RheumNow #APLAR25 #osteoporosis https://t.co/hGMExyDYUX
sheila @RHEUMarampa ( View Tweet)
From the blog
Podcasts
Ro, Ro, Ro52 (9.12.2025)
ILD and Autoimmune Disease
Future Treatment of ILD
QD clinics on ILD - lessons from the Cliniic
Therapeutic Updates
Watch our 9 video series on ILD Treatment and Guidelines including videos on the ACR ILD Guidelines including caveats and concerns.
Read Post
Structural damage progression in active PsA
Sponsored by Johnson & Johnson
Watch Dr. Philip Mease discuss the impact of structural damage on active PsA and follow along as he reviews clinical trial data
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
